Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

M. Oza, Amit; Cook, Adrian; Pfisterer, Jacobus; Embleton-Thirsk, Andrew; A. Ledermann, Jonathan; Pujade-Lauraine, Éric; B. Kristensen, Gunnar; S. Carey, Mark; Beale, Philip; Cervantes, Andrés; Park‐Simon, Tjoung‐Won; Rustin, Gordon; Joly, Florence; Raza Mirza, Mansoor; Plante, Marie; Quinn, Michael; Poveda, Andrés; C. Jayson, Gordon; Stark, Dan; Marie Swart, Ann; Farrelly, Laura; Kaplan, Richard; Parmar, Mahesh; Perren, Timothy

doi:10.1016/s1470-2045(15)00086-8

Public

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

Published in The Lancet Oncology • Jun 24, 2015

Authors:

Amit M. Oza

Adrian Cook

Jacobus Pfisterer

Abstract

BACKGROUND: The ICON7 trial previously reported improved progression-free survival in women with ovarian cancer with the addition of bevacizumab to standard chemotherapy, with the greatest effect in patients at high risk of disease progression. We report the final overall survival results of the tri...

Subject

Bevacizumab

Medicine

Ovarian cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!